Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pertuzumab”

264 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 264 results

Testing effectiveness (Phase 2)Looking for participantsNCT06927180
What this trial is testing

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Henan Cancer Hospital 180
Not applicableUnknownNCT05656079
What this trial is testing

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

Who this might be right for
Breast Cancer
Shanghai Pudong Hospital 204
Large-scale testing (Phase 3)Active Not RecruitingNCT04784715
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Who this might be right for
Breast Cancer; HER2-positive; Metastatic
AstraZeneca 1,157
Large-scale testing (Phase 3)Ended earlyNCT06038539
What this trial is testing

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Who this might be right for
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Biocon Biologics UK Ltd 55
Early research (Phase 1)Study completedNCT02738970
What this trial is testing

A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

Who this might be right for
Early Breast Cancer
Hoffmann-La Roche 88
Large-scale testing (Phase 3)Active Not RecruitingNCT06057610
What this trial is testing

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-PositiveRecurrent or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 868
Large-scale testing (Phase 3)UnknownNCT05985187
What this trial is testing

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Who this might be right for
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 412
Testing effectiveness (Phase 2)UnknownNCT02689921
What this trial is testing

NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer

Who this might be right for
Breast Neoplasms
Midwestern Regional Medical Center 7
Early research (Phase 1)Study completedNCT02060253
What this trial is testing

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more
Memorial Sloan Kettering Cancer Center 9
Not applicableUnknownNCT05188495
What this trial is testing

Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab

Who this might be right for
HER2-positive Metastatic Breast CancerPreviously Treated With TrastuzumabTrastuzumab Combined With Pertuzumab and Chemotherapy
Peking University Cancer Hospital & Institute 60
Not applicableEnded earlyNCT03619044
What this trial is testing

The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.

Who this might be right for
HER2-positive Breast Cancer
Institut Claudius Regaud 4
Post-approval studies (Phase 4)Study completedNCT02445586
What this trial is testing

Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 52
Large-scale testing (Phase 3)Active Not RecruitingNCT03595592
What this trial is testing

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

Who this might be right for
Invasive Breast Cancer
Fondazione Michelangelo 650
Large-scale testing (Phase 3)Active Not RecruitingNCT05426486
What this trial is testing

ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Who this might be right for
HER2-positive Breast Cancer
Caigang Liu 136
Testing effectiveness (Phase 2)Study completedNCT05730712
What this trial is testing

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Mayo Clinic 7
Not applicableStudy completedNCT07115095
What this trial is testing

Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Nanlin Li 98
Large-scale testing (Phase 3)Looking for participantsNCT05256225
What this trial is testing

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Who this might be right for
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI) 360
Testing effectiveness (Phase 2)Looking for participantsNCT05325632
What this trial is testing

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Who this might be right for
HER2-positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 53
Not applicableLooking for participantsNCT06197581
What this trial is testing

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

Who this might be right for
Breast Cancer, Familial MaleRadiotherapy; ComplicationsChemotherapeutic Toxicity+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 148
Testing effectiveness (Phase 2)Active Not RecruitingNCT06172127
What this trial is testing

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
MedSIR 165
Load More Results